




Cysteamine eye drops in the treatment of cystinosis – an Australian perspective

Branko Radojkovic First published: 29 December 2015 | <https://doi.org/10.1002/jppr.1148> | Cited by: 3[Read the full text >](#)
 PDF
  TOOLS
  SHARE


Volume 45, Issue 4
December 2015
Pages 440-445



Related



Information

Abstract

Cystinosis is a rare but very serious genetic disorder. Advancements in medical science, in the past few decades, have transformed this previously terminal condition into a manageable disease. Ophthalmic sequelae of cystinosis are caused by accumulation of cystine crystals in ocular tissues and are very troublesome for most cystinosis patients. Accumulation of crystals in the cornea causes debilitating photophobia and pain that does not respond to systemic cysteamine therapy. If left untreated, this can lead to structural damage (corneal ulcers, scarring and band keratopathy) and eventually result in corneal blindness requiring corneal transplant. Topical ophthalmic application of cysteamine can alleviate the symptoms and, if instituted early, may prevent the damage. There is no commercially manufactured ophthalmic cysteamine product available in Australia and patients who receive treatment are usually supplied with extemporaneously prepared cysteamine eye drops or ointment. Stability issues, various factors influencing product effectiveness and patient adherence are only few of the problems that make formulation and compounding of cysteamine ophthalmic products a complex task.



Citing Literature

Number of times cited: 3

Susmito Biswas, Martha Gaviira, Luisa Malheiro, João Pedro Marques, Vincenzo Giordano and Hong Liang, Latest Clinical Approaches in the Ocular Management of Cystinosis: A Review of Current Practice and Opinion from the Ophthalmology Cystinosis Forum, *Ophthalmology and Therapy*, 10.1007/s40123-018-0146-6, **7**, 2, (307-322), (2018).
[Crossref](#)

Katherine A. Lyseng-Williamson, Cystadrops® (cysteamine hydrochloride 0.55% viscous eye-drops solution) in treating corneal cystine crystal deposits in patients with cystinosis: a profile of its use, *Drugs & Therapy Perspectives*, **33**, 5, (195), (2017).
[Crossref](#)

Susmito Biswas and Krishanthi Sornalingam, The Ocular Status of Cystinosis Patients Receiving a Hospital Pharmacy-Made Preparation of Cysteamine Eye Drops: A Case Series, *Ophthalmology and Therapy*, 10.1007/s40123-018-0156-4, (2018).
[Crossref](#)

[About Wiley Online Library](#)[Privacy Policy](#)[Terms of Use](#)[Cookies](#)[Help & Support](#)[Contact Us](#)[Opportunities](#)[Subscription Agents](#)[Advertisers & Corporate Partners](#)[Connect with Wiley](#)[The Wiley Network](#)[Wiley Press Room](#)

Accessibility

Copyright © 1999-2019 John Wiley & Sons, Inc. All rights reserved